Literature DB >> 15848741

Translocation carcinomas of the kidney.

Pedram Argani1, Marc Ladanyi.   

Abstract

A significant proportion of RCCs of children and young adults bear specific chromosome translocations that result in gene fusions that involve members of the MiTF/TFE transcription factor family. These include the Xp11-translocation carcinomas, which bear TFE3 gene fusions, and the renal carcinomas with the t(6;11)(p21;q12), which bear an Alpha-TFEB gene fusion. Both types of translocation result in overexpression of the fusion gene products, such that nuclear labeling for TFE3 or TFEB by immunohistochemistry is a sensitive and specific marker of these respective tumor types. The clinical behavior of these neoplasms relative to conventional, adult-type renal carcinomas remains to be determined, and will be an important area of future investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15848741     DOI: 10.1016/j.cll.2005.01.008

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  55 in total

Review 1.  Renal cell carcinoma with leiomyomatous stroma: a review of an emerging entity distinct from clear cell conventional renal cell carcinoma.

Authors:  Yunshin A Yeh; Michael Constantinescu; Catherine Chaudoir; Anthony Tanner; Faye Serkin; Xiuping Yu; Tajammul Fazili; Aubrey A Lurie
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

2.  TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.

Authors:  Yongcan Xu; Qiu Rao; Qiuyuan Xia; Shanshan Shi; Qunli Shi; Henghui Ma; Zhenfeng Lu; Hui Chen; Xiaojun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Renal cell carcinoma with t(X;17)(p11.2;q25) in a 5-year-old Taiwanese boy: a case report and review of the literature.

Authors:  Chih-Jung Chen; Hui-Ting Hsu; Ming-Tsan Lin; Mariann Pintye; Jim-Ray Chen
Journal:  Pathol Oncol Res       Date:  2011-01-08       Impact factor: 3.201

Review 4.  Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.

Authors:  Simon Chowdhury; Marc R Matrana; Christopher Tsang; Bradley Atkinson; Toni K Choueiri; Nizar M Tannir
Journal:  Hematol Oncol Clin North Am       Date:  2011-08       Impact factor: 3.722

5.  Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2.

Authors:  James I Geller; Peter F Ehrlich; Nicholas G Cost; Geetika Khanna; Elizabeth A Mullen; Eric J Gratias; Arlene Naranjo; Jeffrey S Dome; Elizabeth J Perlman
Journal:  Cancer       Date:  2015-04-06       Impact factor: 6.860

6.  Translocation renal cell carcinomas in adults: a single-institution experience.

Authors:  Minghao Zhong; Patricia De Angelo; Lisa Osborne; Alberto E Paniz-Mondolfi; Matthew Geller; Youfeng Yang; W Marston Linehan; Maria J Merino; Carlos Cordon-Cardo; Dongming Cai
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

Review 7.  Oncogenic gene fusions in epithelial carcinomas.

Authors:  John R Prensner; Arul M Chinnaiyan
Journal:  Curr Opin Genet Dev       Date:  2009-02-21       Impact factor: 5.578

8.  Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: A case report.

Authors:  Xiang Pan; Jing Quan; Liwen Zhao; Wenhua Li; Benlin Wei; Shangqi Yang; Yongqing Lai
Journal:  Mol Clin Oncol       Date:  2017-11-13

Review 9.  Children's Oncology Group's 2013 blueprint for research: renal tumors.

Authors:  Jeffrey S Dome; Conrad V Fernandez; Elizabeth A Mullen; John A Kalapurakal; James I Geller; Vicki Huff; Eric J Gratias; David B Dix; Peter F Ehrlich; Geetika Khanna; Marcio H Malogolowkin; James R Anderson; Arlene Naranjo; Elizabeth J Perlman
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

10.  Chaperone-mediated autophagy targets hypoxia-inducible factor-1α (HIF-1α) for lysosomal degradation.

Authors:  Maimon E Hubbi; Hongxia Hu; Ishrat Ahmed; Andre Levchenko; Gregg L Semenza
Journal:  J Biol Chem       Date:  2013-03-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.